The 36th International Papillomavirus Conference (IPVC 2024) is dedicated to papillomaviruses and their associated diseases.
The 36th International Papillomavirus Conference (IPVC 2024) covers topics such as:
- Clinical Research
- HPV diagnostics and biomarkers II: Validation platforms (e.g. Valgent)
- HPV diagnostics and biomarkers I: HPV triage technologies
- HPV self-collection
- HPV diagnostics and biomarkers III: Quality and performance verification for clinical HPV tests
- Diagnosis and management of anal cancer and its precursors
- Diagnosis and management of cervical cancer and its precursors
- Diagnosis and management of oropharyngeal, head and neck cancer
- Diagnosis and management of penile, vulvar and vaginal cancer and precursors
- Diagnosis and management of HPV associated skin lesions other than warts
- Diagnosis and management of genital and skin warts
- Therapeutic vaccines - clinical aspects
- Prophylactic vaccines - clinical aspects
- Treatment of precancer in low resource settings
- Management of HPV disease in HIV-infected people
- Treatment of HPV-related disease
- Cochrane reviews of HPV vaccination and screening
- Recurrent Respiratory Papillomatosis
- Other clinical research
- Basic Research
- Animal models
- Taxonomy
- Regulation of gene expression
- Immunology
- Structural biology
- Transformation and carcinogenesis
- Virus life cycle
- Virus - host interactions
- Papillomavirus vaccines (i.e. new developments)
- Genomics of HPV-associated disease
- Other basic research
- High resource settings
- Vaccination: implementation, evaluation and impact
- Screening for HPV related disease: implementation, evaluation and impact
- Primary HPV vs co-testing with HPV and cytology
- Economics and mathematical modelling in HIC
- Screening for HPV related disease screening: implementation, evaluation and impact`
- Low and middle income (LMIC) settings
- Cervical screening and combined screening vaccination strategies in LMIC
- Scale up of HPV vaccination in Gavi-eligible countries
- Vaccine and screening implementation in non GAVI-eligible/middle income countries
- Economics and mathematical modelling for LMIC
- Psychosocial impact of new HPV and cervical cancer prevention strategies
- Other public health / epidemiology research
- Public Health / Epidemiology
- Epidemiology: natural history/global burden/risk factors
- Global impact of HPV and cervical cancer prevention
- Vaccine safety: new evidence and public perception
- Screening for HPV related disease: implementation, evaluation and impact
- Cancer control in Indigenous peoples
- Quality standards and methods for economics and mathematical modelling (e.g. HPV-FRAME)
- Cancer control in Culturally And Linguistically Diverse Groups (CALD)